DrugPatentWatch Database Preview
Antares Pharma Inc Company Profile
What is the competitive landscape for ANTARES PHARMA INC, and when can generic versions of ANTARES PHARMA INC drugs launch?
ANTARES PHARMA INC has two approved drugs.
There are thirteen US patents protecting ANTARES PHARMA INC drugs.
There are thirty-four patent family members on ANTARES PHARMA INC drugs in twelve countries.
Summary for Antares Pharma Inc
| International Patents: | 34 |
| US Patents: | 13 |
| Tradenames: | 3 |
| Ingredients: | 2 |
| NDAs: | 2 |
| Patent Litigation for Antares Pharma Inc: | See patent lawsuits for Antares Pharma Inc |
Drugs and US Patents for Antares Pharma Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-003 | Oct 11, 2013 | RX | Yes | Yes | 8,480,631 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-004 | Oct 11, 2013 | RX | Yes | Yes | 7,776,015 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-004 | Oct 11, 2013 | RX | Yes | Yes | 6,746,429 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-002 | Oct 11, 2013 | RX | Yes | Yes | 7,776,015 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-006 | Mar 24, 2016 | RX | Yes | Yes | 8,579,865 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-005 | Nov 7, 2014 | DISCN | Yes | No | 9,629,959 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-003 | Oct 11, 2013 | RX | Yes | Yes | RE44846 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Non-Orange Book US Patents for Antares Pharma Inc
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 9,750,881 | Hazardous agent injection system | ➤ Sign Up |
| 6,428,528 | Needle assisted jet injector | ➤ Sign Up |
| 9,180,259 | Prefilled syringe jet injector | ➤ Sign Up |
| 6,565,553 | Needle assisted jet injector | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Antares Pharma Inc Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| South Korea | 20070117543 | ➤ Sign Up |
| Japan | 5732039 | ➤ Sign Up |
| Japan | 5216328 | ➤ Sign Up |
| Spain | 2229183 | ➤ Sign Up |
| Japan | 2016104214 | ➤ Sign Up |
| European Patent Office | 1850892 | ➤ Sign Up |
| South Korea | 101597672 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.
